Panelists debate rewards, risks of milestone deals

AMSTERDAM — Venture capitalists do not generally like structured deals that stretch out payments when transitioning acquisitions, thus putting the payments at risk. However, such milestone deals can be successful, a representative of such a firm told colleagues here.“Venture has been under a lot of pressure because of low return, particularly in life sciences,” panelist Gil Kliman, a general partner with Interwest Partners, said at the Ophthalmology Futures European Forum. “So one of the pros of having a structured deal is that it allows us to get more ‘exits,’ by (Read more...)

Full Story →